4 ms·
I doubt it was that much at a loss to warrant a 55x price increase, though. Even 2x is kind of a stretch, although I can see making up for past sales or somethi
by mynameisvlad 11y ago
I doubt it was that much at a loss to warrant a 55x price increase, though. Even 2x is kind of a stretch, although I can see making up for past sales or something (or they were being really generous before).
- cbhl 11y agoThe numbers you need are in the article: $10M loss over 8 years (2007-present), ~45 cases/year. In order to break even, they need to increase the cost of a course of treatment by about ~$28k/patient. The new price doubles the price to about ~$50k/patient, which is still short of this number (but bleeding $3k*45 patients = $135k/year is much more manageable than bleeding $1M dollars a year).
- refurb 11y agoI applaud you sir! Rather than jumping on the hysteria bandwagon, you actually did the math. So even if the drug was priced at $28K/patient, the company would be making zero profit. Huh...
- manigandham 11y ago28k is the delta needed. 53k/patient is break-even.